All In Biotech

Drug Trial Radar · NCT06801249

Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome

"Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Subclinical/Mild Cushing's Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Feb 23, 2021

Primary completion

Nov 30, 2024

Study completion Feb 17, 2025

Sponsor

Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di BolognaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome

Conditions

  • Adrenal Incidentalomas
  • Cushing Syndrome

Interventions

  • MetaraponeDrug

    Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase, which is deputed to catalyze the conversion of 11-desoxycortisol (11-S) to cortisol and 11-deoxycorticosterone (DOC) to corticosterone.

  • Standardized antihypertensive therapyDrug

    Standardized antihypertensive therapy, as provided in the normal course of care and in accordance with current European guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Number and/or Dosage of Antihypertensive Drugs at 12 Months with Metirapone Treatment, Maintaining Target Blood Pressure RangeTime frame: through study completion, an average of 2 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Italy · Recruiting

  • Azienda Ospedale-Università Padova

    Padova, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.